BDC-4182

N/A

Report date: 2025/05/21 11:12:30

Base Information

Drug NameBDC-4182
Drug Alias NameBDC-4182BD-4182
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18Tubulin polymerisation inhibitors
TargetsClaudin-18 splice variant 2Tubulin
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBolt Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBolt Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma +[4
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A